ADVENTRX COFACTOR PHASE IIB TRIAL MOVES FORWARD

Adventrx Pharmaceuticals has announced data from its CoFactor clinical study. Patient recruitment has surpassed the halfway point in the CoFactor multinational Phase IIb clinical trial for metastatic colorectal cancer, which was initiated in May 2005.

The company also has reported an update regarding its planned Phase III clinical studies for CoFactor. The first Phase III study will evaluate CoFactor in the first-line treatment of metastatic colorectal cancer. The second proposed Phase III study would evaluate CoFactor in a third-line setting for advanced breast cancer. CoFactor (ANX-510) is a folate-based biomodulator being developed to enhance the activity and to reduce the toxicity of the widely used chemotherapy drug, 5-fluorouracil.